Modulation of function of the activated first component of complement by a fragment derived from serum. I. Effect on early components of complement.
An activity designated Kf can be separated from human serum and shown to give a 100-300% enhancement in the hemolytic activity of fully activated, fractionated C1. The enhancement of C1 activity is not because of activation of precursor C1 and it is not attributable to an effect on C1 binding. EAC42 or EAC4 intermediates interacted with C1Kf exhibit a greater T(max) and shorter Z(max) than when such intermediates are reacted with the same number of hemolytic units of C1. C3 consumption by the EAC1Kf42 intermediate greatly exceeds that of the EAC142 intermediate produced from the same EAC4 cells by comparable inputs of the other two complement components. Taken together, these findings suggest that Kf-treated C1 achieves more efficient utilization of C4 and C2 to create a larger number of 42 sites as appreciated on the intermediates by shorter T(max) and a greater Z(max), and an increased capacity to utilize C3. The capacity of Kf to enhance C1 upon introduction into whole serum of a patient with hereditary angioedema (HAE) in a manner comparable to its effect on fractionated C1 suggests that the effect of Kf may be pertinent to certain pathophysiologic conditions of man.
D000799:Angioedema / Q000276:immunology; D000818:Animals; D002848:Chromatography, DEAE-Cellulose; D002850:Chromatography, Gel; D003165:Complement System Proteins / Q000502:physiology*; D006168:Guinea Pigs; D006461:Hemolysis; D006801:Humans; D007111:Immunity, Cellular; D007120:Immunochemistry; D007610:Kallikreins; D007705:Kinins / Q000097:blood; D012756:Sheep; D013025:Glycine max; D013053:Spectrophotometry; D014361:Trypsin Inhibitors
D007705:Kinins; D014361:Trypsin Inhibitors; D003165:Complement System Proteins; D007610:Kallikreins